Vivanza Biosciences Limited (BOM:530057)
2.100
-0.050 (-2.33%)
At close: Jan 20, 2026
Vivanza Biosciences Revenue
Vivanza Biosciences had revenue of 553.65M INR in the quarter ending September 30, 2025, with 1,743.97% growth. This brings the company's revenue in the last twelve months to 663.49M, up 304.13% year-over-year. In the fiscal year ending March 31, 2025, Vivanza Biosciences had annual revenue of 74.72M, down -73.21%.
Revenue (ttm)
663.49M
Revenue Growth
+304.13%
P/S Ratio
0.13
Revenue / Employee
82.94M
Employees
8
Market Cap
86.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 74.72M | -204.18M | -73.21% |
| Mar 31, 2024 | 278.89M | 97.35M | 53.62% |
| Mar 31, 2023 | 181.54M | 69.55M | 62.10% |
| Mar 31, 2022 | 111.99M | 12.60M | 12.67% |
| Mar 31, 2021 | 99.40M | 3.19M | 3.31% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sunrest Lifescience | 520.34M |
| Cian Healthcare | 232.80M |
| Beryl Drugs | 191.97M |
| Decipher Labs | 176.11M |
| Brawn Biotech | 168.03M |
| Unjha Formulations | 141.50M |
| Norris Medicines | 72.84M |
| Colinz Laboratories | 58.72M |